



HC Wainright & Co Virtual Conference Presentation
September 10, 2020 11:00 AM EDT

Released : September 10, 2020 07:00

RNS Number : 5403Y
MaxCyte, Inc.
10 September 2020

MaxCyte to Present at Upcoming 2020 H.C. Wainright & Co 22nd Annual Global Investment Virtual Conference

GAITHERSBURG, MD, 10 September 2020 - MaxCyte, Inc. (LSE: MXCT, MXCL), a global cell-based therapies and life sciences company, today announced that CEO Doug Doerfler plans to present an overview of the company at the upcoming H.C. Wainright & Co 22nd Annual Global Investment Virtual Conference taking place September 14-16, 2020. Details are as follows:

Presentation Date/Time: Monday, September 14, at 4:00 p.m. EDT
Online access: <https://wsw.com/webcast/hcw7/maxcyte/2019107>

About MaxCyte

MaxCyte is a clinical-stage global cell-based therapies and life sciences company. As the inventors of the premier cell-engineering enabling technology, the Company helps bring the promise of next-generation cell and gene-editing therapies to life. The Company's technology is currently being deployed by leading drug developers worldwide, including all of the top ten global biopharmaceutical companies. MaxCyte licences have been granted for more than 120 cell therapy programmes, with more than 90 licensed for clinical use, and the Company has now entered into eleven clinical/commercial license partnerships with leading cell therapy and gene editing developers. MaxCyte was founded in 1998, is listed on the London Stock Exchange (LSE: MXCT, MXCL) and is headquartered in Gaithersburg, Maryland, US. For more information, visit www.maxcyte.com.

Contacts:

MaxCyte Inc.
Doug Doerfler, Chief Executive Officer

+1 301-944-1660

Amanda Murphy, Chief Financial Officer

Nominated Adviser and Joint Corporate Broker

Panmure Gordon

+44 (0)20 7886 2500

Emma Earl

Freddy Crossley

Corporate Broking

Rupert Dearden

Joint Corporate Broker

Numis Securities Limited

+44 (0)20 7260 1000

James Black

Duncan Monteith

Financial PR Adviser

+44 (0)203 709 5700

Consilium Strategic Communications

maxcyte@consilium-com

Mary-Jane Elliott

Chris Welsh

Ashley Tapp

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Private Policy](#).

END

NRAKKCBNOBKDBCK